VIRxSYS has raised over $100 million through equity and debt financing thanks to the support of our investors. Without their continued support and enthusiasm, the Company would not be able to develop technology that delivers on the promise of genetic medicine, allowing for the treatment of serious human diseases.
Technology Advancement
VIRxSYS intends to develop technology internally and acquire technology which fit an "SSD" strategy. SSD refers to the following:
- Strategic – must help us drive the Company towards its mission
- Synergistic – must take advantage of the Company's core competencies in RNA payloads and delivery technologies
- Disruptive – must provide a significant and unique therapeutic advantage
Business Model
VIRxSYS’s strategy is to develop human therapies for serious diseases and advance each of those therapies into the market along one of three avenues:
- Exclusive licensing to, or partnering with, a major bio-pharmaceutical company
- Non-exclusive licensing to a bio-pharmaceutical company, retaining co-promotion or co-marketing rights for the United States
- Go-it-alone strategy whereby VIRxSYS will take the lead in sales, marketing and distribution
The "go to market" track will depend on a number of factors including, but not limited to:
- Size of the market
- Capital requirements to take to market
- Complexity of the manufacturing and distribution channels
- Strength of potential partners
Each disease indication will be evaluated to determine the most appropriate track.
If you are interested in finding out more information about VIRxSYS, please send us an email at findout@virxsys.com.
"VIRxSYS is in business to take gene therapy from the lab to the market. There are unmet medical needs out there, and we intend to build a vibrant business portfolio serving those needs.
Gerard Fleury, VIRxSYS EVP & CFO